Tryp Therapeutics ( $TRYP ) has begun phase 2 trials of their TRYP-8802 oral formulation with the University of Michigan.
TRYP-8802 is synthetic psilocybin
Tryp and UoM are testing the efficacy of the drug in tandem with psychotherapy for treating fibromyalgia.
This treatment is designed to target neoplastic pain that originates in the central nervous system.
Synthetic psilocybin is expected to help this kind of pain because of psilocybin's neuroplasticity benefits
U Michigan is one of the worlds leading centres of excellence in pain and Tryp's President and Chief Science Officer says they are thrilled to be working with them in this exclusive partnership.
These trials will be the world's first psychedelic clinical trial on Pain and will include research on dosing, route of administration, and formulation.
Full article here: https://www.newsfilecorp.com/release/90865/Tryp-Therapeutics-Announces-Plans-for-Phase-2a-Clinical-Trial-for-Fibromyalgia-with-the-University-of-Michigan